1993
DOI: 10.1126/science.7684163
|View full text |Cite
|
Sign up to set email alerts
|

Present Status and Future Prospects for HIV Therapies

Abstract: Since the discovery of human immunodeficiency virus (HIV) in 1983, significant progress has been made toward the discovery, development, and licensing of anti-HIV drugs. In vitro screens against whole virus are now being complemented by screens against specific viral targets, resulting in the development of clinical candidates acting at several critical stages of the viral life cycle. Despite these advances, clinical therapy remains largely palliative. In addition, it has recently been recognized that HIV resi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
105
0

Year Published

1993
1993
2010
2010

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 185 publications
(105 citation statements)
references
References 213 publications
0
105
0
Order By: Relevance
“…Numerous other RT inhibitors have been described (1), and some of them are in clinical trials. Although these drugs strongly inhibit viral replication in vitro, the long-term benefits of these drugs on clinical progression of disease are uncertain (2). After prolonged therapy, drug-resistant viruses emerge because of point mutations in the polymerase gene that give rise to amino acid changes in RT (3)(4)(5)(6)(7).…”
mentioning
confidence: 99%
“…Numerous other RT inhibitors have been described (1), and some of them are in clinical trials. Although these drugs strongly inhibit viral replication in vitro, the long-term benefits of these drugs on clinical progression of disease are uncertain (2). After prolonged therapy, drug-resistant viruses emerge because of point mutations in the polymerase gene that give rise to amino acid changes in RT (3)(4)(5)(6)(7).…”
mentioning
confidence: 99%
“…Long-term suppression chemotherapy appears to improve the survival of patients with AIDS, but it is difficult to use for long-term chemotherapy. 6) Its major drug-related toxicity is bone marrow suppression, which limits the dose of AZT that can be used.…”
mentioning
confidence: 99%
“…Specificity of expression has already been envisaged using either specific promoters 159 -161 that can direct expression of the transgene in specific cells or inducible promoters, such as those containing a Tat activating region element, whose expression is induced by the HIV Tat protein. 162,163 Long-term expression of the transgene has to be addressed through the analysis of factors involved in the decrease of transgene expression, 164 -166 such as the hypermethylation of DNA, 167,168 or interferences between cotransferred promoters. 169 New vector designs have already resulted from these studies but remain to be fully tested with primary hematopoietic cells.…”
Section: Discussionmentioning
confidence: 99%